Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: NSUN2

Gene summary for NSUN2

Gene summary.

Gene information	Species	Human
	Gene symbol	NSUN2
	Gene ID	54888
	Gene name	NOP2/Sun RNA methyltransferase 2
	Gene Alias	MISU
	Cytomap	5p15.31
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	Q08J23

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
54888	NSUN2	HTA11_1938_2000001011	Human	Colorectum	AD	1.00e-07	5.36e-01	-0.0811
54888	NSUN2	HTA11_78_2000001011	Human	Colorectum	AD	2.32e-05	4.29e-01	-0.1088
54888	NSUN2	HTA11_347_2000001011	Human	Colorectum	AD	2.66e-14	5.13e-01	-0.1954
54888	NSUN2	HTA11_696_2000001011	Human	Colorectum	AD	3.16e-04	3.37e-01	-0.1464
54888	NSUN2	HTA11_1391_2000001011	Human	Colorectum	AD	8.90e-05	4.11e-01	-0.059
54888	NSUN2	HTA11_10711_2000001011	Human	Colorectum	AD	2.10e-03	3.70e-01	0.0338
54888	NSUN2	HTA11_6818_2000001011	Human	Colorectum	AD	9.21e-03	4.32e-01	0.0112
54888	NSUN2	HTA11_6818_2000001021	Human	Colorectum	AD	2.01e-02	3.25e-01	0.0588
54888	NSUN2	HTA11_99999970781_79442	Human	Colorectum	MSS	1.69e-06	3.98e-01	0.294
54888	NSUN2	HTA11_99999965062_69753	Human	Colorectum	MSI-H	6.39e-04	7.74e-01	0.3487
54888	NSUN2	HTA11_99999971662_82457	Human	Colorectum	MSS	6.24e-06	4.58e-01	0.3859
54888	NSUN2	HTA11_99999973899_84307	Human	Colorectum	MSS	8.46e-04	5.84e-01	0.2585
54888	NSUN2	HTA11_99999974143_84620	Human	Colorectum	MSS	4.79e-34	1.10e+00	0.3005
54888	NSUN2	A015-C-203	Human	Colorectum	FAP	8.85e-05	-8.18e-02	-0.1294
54888	NSUN2	A002-C-203	Human	Colorectum	FAP	2.10e-02	-1.32e-01	0.2786
54888	NSUN2	A015-C-104	Human	Colorectum	FAP	1.66e-05	-1.39e-01	-0.1899
54888	NSUN2	A002-C-016	Human	Colorectum	FAP	2.72e-07	-2.19e-01	0.0521
54888	NSUN2	A002-C-116	Human	Colorectum	FAP	9.90e-09	-1.53e-01	-0.0452
54888	NSUN2	F034	Human	Colorectum	FAP	8.94e-05	-1.39e-01	-0.0665
54888	NSUN2	LZE2T	Human	Esophagus	ESCC	7.31e-04	4.89e-01	0.082

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003238616	Oral cavity	LP	regulation of intracellular transport	145/4623	337/18723	8.58e-14	8.27e-12	145
GO:000691318	Oral cavity	LP	nucleocytoplasmic transport	130/4623	301/18723	1.19e-12	9.77e-11	130
GO:005116918	Oral cavity	LP	nuclear transport	130/4623	301/18723	1.19e-12	9.77e-11	130
GO:003465518	Oral cavity	LP	nucleobase-containing compound catabolic process	161/4623	407/18723	1.61e-11	1.15e-09	161
GO:000640119	Oral cavity	LP	RNA catabolic process	118/4623	278/18723	4.98e-11	3.12e-09	118
GO:005065715	Oral cavity	LP	nucleic acid transport	78/4623	163/18723	1.11e-10	6.44e-09	78
GO:005065815	Oral cavity	LP	RNA transport	78/4623	163/18723	1.11e-10	6.44e-09	78
GO:005123615	Oral cavity	LP	establishment of RNA localization	79/4623	166/18723	1.18e-10	6.81e-09	79
GO:001943916	Oral cavity	LP	aromatic compound catabolic process	176/4623	467/18723	1.96e-10	1.08e-08	176
GO:004427017	Oral cavity	LP	cellular nitrogen compound catabolic process	170/4623	451/18723	3.93e-10	2.02e-08	170
GO:004670016	Oral cavity	LP	heterocycle catabolic process	168/4623	445/18723	4.35e-10	2.20e-08	168
GO:0009895110	Oral cavity	LP	negative regulation of catabolic process	128/4623	320/18723	8.36e-10	3.91e-08	128
GO:000170117	Oral cavity	LP	in utero embryonic development	142/4623	367/18723	1.48e-09	6.75e-08	142
GO:001593115	Oral cavity	LP	nucleobase-containing compound transport	95/4623	222/18723	2.23e-09	9.98e-08	95
GO:190136116	Oral cavity	LP	organic cyclic compound catabolic process	180/4623	495/18723	3.11e-09	1.35e-07	180
GO:0031330110	Oral cavity	LP	negative regulation of cellular catabolic process	107/4623	262/18723	5.25e-09	2.16e-07	107
GO:005102814	Oral cavity	LP	mRNA transport	62/4623	130/18723	1.03e-08	3.90e-07	62
GO:004682218	Oral cavity	LP	regulation of nucleocytoplasmic transport	52/4623	106/18723	4.82e-08	1.67e-06	52
GO:005116818	Oral cavity	LP	nuclear export	68/4623	154/18723	9.55e-08	3.13e-06	68
GO:007116611	Oral cavity	LP	ribonucleoprotein complex localization	38/4623	77/18723	2.47e-06	5.43e-05	38

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

NSUN2

SNV

Missense_Mutation

c.1876N>A

p.Asp626Asn

p.D626N

Q08J23

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-A2-A0CR-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

NSUN2

SNV

Missense_Mutation

rs745927756

c.658N>T

p.Arg220Cys

p.R220C

Q08J23

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

NSUN2

SNV

Missense_Mutation

novel

c.2117N>G

p.Val706Gly

p.V706G

Q08J23

protein_coding

deleterious(0.01)

benign(0.141)

TCGA-AO-A1KP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

fluorouracil

NSUN2

SNV

Missense_Mutation

rs759251595

c.2008N>T

p.Ala670Ser

p.A670S

Q08J23

protein_coding

tolerated(0.76)

benign(0.02)

TCGA-E9-A2JS-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cyclophosphamide

NSUN2

insertion

Nonsense_Mutation

novel

c.1617_1618insTTTCATCTTATTTTTTTACTTACAGGTTATTAACACA

p.Asp540PhefsTer11

p.D540Ffs*11

Q08J23

protein_coding

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

NSUN2

deletion

Frame_Shift_Del

novel

c.403delN

p.Ile135SerfsTer2

p.I135Sfs*2

Q08J23

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

NSUN2

SNV

Missense_Mutation

rs746142475

c.2167G>A

p.Ala723Thr

p.A723T

Q08J23

protein_coding

tolerated(0.19)

benign(0.003)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

NSUN2

SNV

Missense_Mutation

novel

c.259G>A

p.Ala87Thr

p.A87T

Q08J23

protein_coding

deleterious(0.04)

possibly_damaging(0.616)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

NSUN2

SNV

Missense_Mutation

c.178N>A

p.Glu60Lys

p.E60K

Q08J23

protein_coding

deleterious(0.01)

benign(0.091)

TCGA-C5-A1BQ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

NSUN2

SNV

Missense_Mutation

novel

c.2001N>G

p.Asn667Lys

p.N667K

Q08J23

protein_coding

tolerated(0.93)

benign(0)

TCGA-VS-A8EK-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1